Merck & Co’s (NYSE: MRK) gamble on an early bid to bring the first ever dual chemo and immuno-oncology therapy to market has paid off.
The US Food and Drug Administration has granted approval to market Keytruda (pembrolizumab) as a first-line dual therapy for advanced non-small cell lung cancer (NSCLC) patients.
Clinical trials showed that Keytruda plus chemotherapy drugs Alimta (pemetrexed) and carboplatin produced an improved response from patients. Alimta is manufactured by Eli Lilly (NYSE: LLY).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze